NASDAQ:FURX - Furiex Pharmaceuticals Stock Price, News, & Analysis Sign in or create an account to add this stock to your watchlist. Get Started Previous CloseN/AToday's RangeN/A52-Week RangeN/AVolumeN/AAverage VolumeN/AMarket CapitalizationN/AP/E RatioN/ADividend YieldN/ABetaN/A Company ProfileChartEarnings HistoryFinancialsInsider TradesHeadlinesOptions ChainSEC FilingsSocial Media Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email Furiex Pharmaceuticals, Inc. is a drug development collaboration company. The Company's product pipeline includes two marketed products and three programs in development, including late-stage compounds, in multiple therapeutic areas. Its programs include Priligy, Alogliptin Nesina, Alogliptin/Actose Combination, Alogliptin/Metformin Combination, Fluoroquinolone, Mu Delta and PPD 10558. In November 2011, it acquired full exclusive license rights to develop and commercialize the compound MuDelta under its existing development and license agreement with Janssen Pharmaceutica N.V. Effective July 2, 2014 Forest Laboratories Inc, a unit of Actavis PLC, acquired the entire share capital of Furiex Pharmaceuticals Inc. Receive FURX News and Ratings via Email Sign-up to receive the latest news and ratings for FURX and its competitors with MarketBeat's FREE daily newsletter. Industry, Sector and Symbol Stock Exchange NASDAQ Industry N/A Sub-IndustryLife Sciences Tools & Services SectorN/A SymbolNASDAQ:FURX CUSIP36106P10 WebN/A Phone+1-919-4567800 Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / CashN/A Book ValueN/A Price / BookN/A Profitability EPS (Most Recent Fiscal Year)N/A Net IncomeN/A Net MarginsN/A Return on EquityN/A Return on AssetsN/A Miscellaneous EmployeesN/A Outstanding SharesN/AMarket Cap$0.00 Furiex Pharmaceuticals (NASDAQ:FURX) Frequently Asked Questions What is Furiex Pharmaceuticals' stock symbol? Furiex Pharmaceuticals trades on the NASDAQ under the ticker symbol "FURX." Has Furiex Pharmaceuticals been receiving favorable news coverage? News articles about FURX stock have trended somewhat positive on Tuesday, Accern reports. The research firm identifies positive and negative media coverage by reviewing more than twenty million news and blog sources in real time. Accern ranks coverage of public companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Furiex Pharmaceuticals earned a media and rumor sentiment score of 0.16 on Accern's scale. They also gave news headlines about the healthcare company an impact score of 47.89 out of 100, meaning that recent media coverage is somewhat unlikely to have an impact on the stock's share price in the next several days. View Recent Headlines for Furiex Pharmaceuticals. How do I buy shares of Furiex Pharmaceuticals? Shares of FURX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab. How can I contact Furiex Pharmaceuticals? Furiex Pharmaceuticals' mailing address is 3900 Paramount Pkwy Ste 150, MORRISVILLE, NC 27560-5401, United States. The healthcare company can be reached via phone at +1-919-4567800. MarketBeat Community Rating for Furiex Pharmaceuticals (NASDAQ FURX)Community Ranking: 2.8 out of 5 ( )Outperform Votes: 86 (Vote Outperform)Underperform Votes: 67 (Vote Underperform)Total Votes: 153MarketBeat's community ratings are surveys of what our community members think about Furiex Pharmaceuticals and other stocks. Vote "Outperform" if you believe FURX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe FURX will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 8/21/2018 by MarketBeat.com StaffFeatured Article: Do closed-end mutual funds pay dividends?